Report overview
Atypical antipsychotic drugs are a type of antipsychotic drugs used in treatment of psychosis. They do not cure psychosis but help in controlling symptoms such as hallucinations, and delusions, among others.
This report contains market size and forecasts of Atypical Antipsychotic Drugs in global, including the following market information:
Global Atypical Antipsychotic Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Atypical Antipsychotic Drugs Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Atypical Antipsychotic Drugs companies in 2021 (%)
The global Atypical Antipsychotic Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Risperidone Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Atypical Antipsychotic Drugs include Novartis AG, Cardinal Health, Johnson and Johnson, Allergan, Sanis Health, Pfizer, GlaxoSmithKline, Bristol-Myers Squibb Company and Sun Pharmaceutical Industries, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Atypical Antipsychotic Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Atypical Antipsychotic Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Atypical Antipsychotic Drugs Market Segment Percentages, by Type, 2021 (%)
Risperidone
Olanzapine
Quetiapine
Ziprasidone
Others
Global Atypical Antipsychotic Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Atypical Antipsychotic Drugs Market Segment Percentages, by Application, 2021 (%)
Bipolar I Disorder
Schizophrenia
Schizoaffective Disorder
Major Depressive Disorder (MDD)
Global Atypical Antipsychotic Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Atypical Antipsychotic Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Atypical Antipsychotic Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Atypical Antipsychotic Drugs revenues share in global market, 2021 (%)
Key companies Atypical Antipsychotic Drugs sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Atypical Antipsychotic Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis AG
Cardinal Health
Johnson and Johnson
Allergan
Sanis Health
Pfizer
GlaxoSmithKline
Bristol-Myers Squibb Company
Sun Pharmaceutical Industries
Eil Lilly and Company
AstraZeneca
Sumitomo Dainippon Pharma
Qilu Pharmaceutical
